DUBLIN, Apr. 15, 2014 /PRNewswire/ --
Research and Markets
) has announced the addition of the
report to their offering.
The analysts forecast the Global Hyaluronic Acid market to grow at a CAGR of 9.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in aging population. The Global Hyaluronic Acid market has also been witnessing the shift to shorter treatment regimens. However, the intense price competition could pose a challenge to the growth of this market.
The report, Global Hyaluronic Acid Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hyaluronic Acid market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The Global HA market will continue to witness a shift toward premium-priced shorter treatment regimens. Such regimes provide more convenience to the patients and result in a rise in patient acceptance of HA viscosupplementation treatment for OA. Shorter treatment regimens using premium-priced triple and single-injection products will add to the overall increase in revenues in the Global HA market during the forecast period.
Patients suffering from OA in the US have widely accepted Sanofi's Synvisc-One and other single-injection products such as Monovisc and Gel-200, which have led to an increase in US shares in the Global HA market. In addition, recent approvals of TRB Chemedica's Ostenil Plus, Anika Therapeutics' Monovisc, and Sanofi's Synvisc-One for use in Europe are expected to drive the market.
Further, Anika launched Monovisc in Taiwan in 2012 and Sanofi is planning to launch Synvisc-One in South Korea by 2015, which will further drive the market. Thus, shorter treatment regimens will help in sustaining the market during the forecast period.
According to the report, one of the main drivers in this market is the steadily growing aging population globally. Aging is one of the main causes for the high demand for HA viscosupplementation. OA affects the aging population to a great extent. Viscosupplementation helps in decreasing pain and improving function in patients with knee OA. The global demand for HA viscosupplementation is expected to increase due to the rapidly increasing aging population in different parts of the world.
Further, the report states that one of the major challenges faced by the market is the intense price competition. The intense price competition limits the ASP of HA viscosupplements. This in turn, brings down the ASPs of viscosupplements and the players undergo significant losses.
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Key Leading Countries
9. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Key Vendor Analysis
17. Other Reports in this Series
- Anika Therapeutics Inc.
- Contipro Biotech Sro
- Ferring Pharmaceuticals Inc.
- Fidia farmaceutici SpA
- Lifecore Biomedical LLC
- Novozymes A/S.
- Sanofi SA
- Shandong Freda Biochem Co. Ltd
- TRB Chemedica International SA
- Teijin Pharma Ltd.
- eikagaku Corp.
- htl BIOTECHNOLOGY
For more information visit http://www.researchandmarkets.com/research/v69skh/global_hyaluronic
Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets